Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018.

Becker JC, Eigentler T, Frerich B, Gambichler T, Grabbe S, Höller U, Klumpp B, Loquai C, Krause-Bergmann A, Müller-Richter U, Pföhler C, Schneider-Burrus S, Stang A, Terheyden P, Ugurel S, Veith J, Mauch C.

J Dtsch Dermatol Ges. 2019 May;17(5):562-577. doi: 10.1111/ddg.13841_g.

PMID:
31115985
2.

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018.

Becker JC, Eigentler T, Frerich B, Gambichler T, Grabbe S, Höller U, Klumpp B, Loquai C, Krause-Bergmann A, Müller-Richter U, Pföhler C, Schneider-Burrus S, Stang A, Terheyden P, Ugurel S, Veith J, Mauch C.

J Dtsch Dermatol Ges. 2019 May;17(5):562-576. doi: 10.1111/ddg.13841. Epub 2019 May 6.

PMID:
31056838
3.

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.

Engel S, Luessi F, Henning B, Bittner S, Loquai C, Zipp F.

Ann Oncol. 2019 Mar 26. pii: mdz114. doi: 10.1093/annonc/mdz114. [Epub ahead of print] No abstract available.

PMID:
30911762
4.

Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas.

Persa OD, Loquai C, Wobser M, Baltaci M, Dengler S, Kreuter A, Volz A, Laimer M, Emberger M, Doerler M, Mauch C, Helbig D.

J Eur Acad Dermatol Venereol. 2019 Feb 14. doi: 10.1111/jdv.15493. [Epub ahead of print]

PMID:
30767327
5.

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

Mohr P, Haferkamp S, Pinter A, Weishaupt C, Huber MA, Downey G, Öhrling K, Loquai C, Louie KS.

Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7.

6.

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L.

Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17.

PMID:
30453170
7.

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.

Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, Rafei-Shamsabadi D, Utikal J, Bergmann M, Meier F, Kreuzberg N, Schlaak M, Weishaupt C, Pföhler C, Ziemer M, Fluck M, Rainer J, Heppt MV, Berking C.

Oncotarget. 2018 Sep 28;9(76):34336-34346. doi: 10.18632/oncotarget.26149. eCollection 2018 Sep 28.

8.

[Liver injury induced by immune checkpoint inhibitor-therapy : Example of an immune-mediated drug side effect].

Straub BK, Ridder DA, Schad A, Loquai C, Schattenberg JM.

Pathologe. 2018 Nov;39(6):556-562. doi: 10.1007/s00292-018-0519-6. Review. German.

PMID:
30310977
9.

Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters.

Schmidberger H, Rapp M, Ebersberger A, Hey-Koch S, Loquai C, Grabbe S, Mayer A.

Strahlenther Onkol. 2018 Dec;194(12):1144-1151. doi: 10.1007/s00066-018-1356-5. Epub 2018 Oct 8.

10.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
11.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
12.

In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET.

Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M.

EJNMMI Res. 2018 Aug 15;8(1):80. doi: 10.1186/s13550-018-0435-z.

13.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.

Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M.

Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25.

14.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC.

PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

15.

Psychoonkologische Versorgung von Melanompatienten in zertifizierten Hautkrebszentren.

Meiss F, Loquai C, Weis J, Giesler JM, Reuter K, Nashan D.

J Dtsch Dermatol Ges. 2018 May;16(5):577-584. doi: 10.1111/ddg.13521_g. No abstract available.

PMID:
29750470
16.

Psycho-oncological care of melanoma patients in certified skin cancer centers.

Meiss F, Loquai C, Weis J, Giesler JM, Reuter K, Nashan D.

J Dtsch Dermatol Ges. 2018 May;16(5):576-582. doi: 10.1111/ddg.13521.

PMID:
29750461
17.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
18.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG).

Cancer Immunol Immunother. 2018 May;67(5):825-834. doi: 10.1007/s00262-018-2134-z. Epub 2018 Feb 27.

PMID:
29487980
19.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

20.

Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.

Lang BM, Peveling-Oberhag A, Faidt D, Hötker AM, Weyer-Elberich V, Grabbe S, Loquai C.

Med Oncol. 2018 Jan 31;35(3):24. doi: 10.1007/s12032-018-1084-9.

PMID:
29387968
21.

S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-123. doi: 10.1111/ddg.13401_g. No abstract available.

PMID:
29314698
22.

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-122. doi: 10.1111/ddg.13401. Epub 2017 Dec 27. No abstract available.

PMID:
29280595
23.

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO).

Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20.

24.

S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273. doi: 10.1111/ddg.13372_g. No abstract available.

PMID:
29228489
25.

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273. doi: 10.1111/ddg.13372. Epub 2017 Nov 28. No abstract available.

PMID:
29193659
26.

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.

Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC.

Oncotarget. 2017 Jun 27;8(44):76029-76043. doi: 10.18632/oncotarget.18635. eCollection 2017 Sep 29.

27.

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.

Heppt MV, Schlaak M, Eigentler TK, Kähler KC, Kiecker F, Loquai C, Meier F, Tomsitz D, Brenner N, Niesert AC, Thonke R, Hauschild A, Berking C.

Ann Oncol. 2017 Dec 1;28(12):3104-3106. doi: 10.1093/annonc/mdx538. No abstract available.

PMID:
28950303
28.

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.

Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.

29.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö.

Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.

PMID:
28678784
30.

Pembrolizumab-induzierter Lichen planus pemphigoides bei einem Patienten mit metastasiertem Melanom.

Schmidgen MI, Butsch F, Schadmand-Fischer S, Steinbrink K, Grabbe S, Weidenthaler-Barth B, Loquai C.

J Dtsch Dermatol Ges. 2017 Jul;15(7):742-745. doi: 10.1111/ddg.13272_g. No abstract available.

PMID:
28677196
31.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
32.

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.

Schmidgen MI, Butsch F, Schadmand-Fischer S, Steinbrink K, Grabbe S, Weidenthaler-Barth B, Loquai C.

J Dtsch Dermatol Ges. 2017 Jul;15(7):742-745. doi: 10.1111/ddg.13272. Epub 2017 Jun 16. No abstract available.

PMID:
28622432
33.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
34.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A.

Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.

35.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M.

Lancet Oncol. 2017 May;18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27.

PMID:
28359784
36.

Interactions from complementary and alternative medicine in patients with melanoma.

Loquai C, Schmidtmann I, Garzarolli M, Kaatz M, Kähler KC, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Nashan D, Stein A, Stoll C, Dechent D, Huebner J.

Melanoma Res. 2017 Jun;27(3):238-242. doi: 10.1097/CMR.0000000000000339.

PMID:
28252553
37.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
38.

Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients.

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Stein A, Nashan D, Stoll C, Schmidtmann I, Huebner J.

Eur J Cancer. 2017 Jan;71:70-79. doi: 10.1016/j.ejca.2016.10.029. Epub 2016 Dec 14.

PMID:
27984769
39.

New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.

Behling J, Kaes J, Münzel T, Grabbe S, Loquai C.

Melanoma Res. 2017 Apr;27(2):155-158. doi: 10.1097/CMR.0000000000000314.

PMID:
27977496
40.

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.

Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Lang BM, Schadendorf D, Stade B, Terheyden P, Utikal J, Wagner T, Hauschild A, Garbe C, Augustin M.

Medicine (Baltimore). 2016 Nov;95(46):e5375.

41.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF.

ESMO Open. 2016 Aug 8;1(4):e000068. eCollection 2016.

42.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.

Eur J Cancer. 2016 Nov;67:46-54. doi: 10.1016/j.ejca.2016.07.018. Epub 2016 Sep 2.

43.

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO).

J Dtsch Dermatol Ges. 2016 Jul;14(7):662-81. doi: 10.1111/ddg.13047.

PMID:
27373241
44.

Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; für das Komitee „Kutane Nebenwirkungen“ der Arbeitsgemeinschaft Dermatologische Onkologie (ADO).

J Dtsch Dermatol Ges. 2016 Jul;14(7):662-83. doi: 10.1111/ddg.13047_g. No abstract available.

PMID:
27373240
45.

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.

Heppt MV, Eigentler TK, Kähler KC, Herbst RA, Göppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schäd SG, Schultz ES, Matheis F, Tietze JK, Berking C.

Cancer Immunol Immunother. 2016 Aug;65(8):951-9. doi: 10.1007/s00262-016-1856-z. Epub 2016 Jun 13.

PMID:
27294607
46.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U.

Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.

PMID:
27281205
47.

Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial.

Huebner J, Mohr P, Simon JC, Fluck M, Berking C, Zimmer L, Loquai C.

J Dtsch Dermatol Ges. 2016 May;14(5):508-13. doi: 10.1111/ddg.12750.

PMID:
27119474
48.

Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen Studie.

Huebner J, Mohr P, Simon JC, Fluck M, Berking C, Zimmer L, Loquai C.

J Dtsch Dermatol Ges. 2016 May;14(5):508-13. doi: 10.1111/ddg.12750_g.

PMID:
27119473
49.

Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma.

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P, Meiss F, Stein A, Nashan D, Micke O, Muecke R, Muenstedt K, Stoll C, Schmidtmann I, Huebner J.

Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18.

PMID:
27090799
50.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.

PMID:
27085692

Supplemental Content

Loading ...
Support Center